Q3 2024 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2024-11-13 · accession 0000950123-24-011026
$666.6M
Reported value
43
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Therapeutics, Inc. | $128.0M | 19.2% | 7,648,268 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $44.9M | 6.74% | 615,391 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $32.0M | 4.80% | 2,680,596 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $31.6M | 4.75% | 688,975 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $26.9M | 4.03% | 525,845 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $24.5M | 3.67% | 917,166 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $22.6M | 3.39% | 2,406,714 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $22.5M | 3.37% | 177,099 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $19.7M | 2.95% | 1,066,373 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $19.2M | 2.88% | 492,723 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $18.3M | 2.75% | 329,733 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $17.8M | 2.67% | 1,745,943 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $17.6M | 2.64% | 349,063 | Common | SOLE |
| 516544103 | LNTH | Lantheus Holdings Inc | $16.5M | 2.47% | 150,182 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals Inc | $15.4M | 2.30% | 72,395 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $15.3M | 2.30% | 311,761 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $14.4M | 2.16% | 2,033,041 | Common | SOLE |
| 90184D100 | TWST | Twist Bioscience Corp | $13.3M | 2.00% | 294,930 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $13.2M | 1.98% | 291,391 | Common | SOLE |
| 40131M109 | GH | Guardant Health Inc | $11.5M | 1.72% | 499,170 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $11.3M | 1.69% | 392,544 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $10.4M | 1.56% | 896,915 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $10.4M | 1.56% | 5,641,894 | Common | SOLE |
| 816212302 | RNAC | Cartesian Therapeutics Inc | $10.1M | 1.52% | 629,423 | Common | SOLE |
| 869367102 | — | Sutro Biopharma, Inc. | $9.8M | 1.47% | 2,832,064 | Common | SOLE |
| 03843E104 | AQST | Aquestive Therapeutics Inc | $8.9M | 1.34% | 1,796,750 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $7.8M | 1.17% | 171,105 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $7.7M | 1.15% | 120,982 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $6.5M | 0.98% | 165,800 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics Inc | $5.9M | 0.88% | 479,452 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $5.6M | 0.85% | 1,639,849 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $5.5M | 0.82% | 267,557 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals, Inc. | $5.4M | 0.81% | 1,465,801 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $5.1M | 0.77% | 1,538,517 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences PTE LTD | $5.1M | 0.77% | 624,471 | Common | SOLE |
| 03969T109 | ARCT | Arcturus Therapeutics Holdings | $5.1M | 0.76% | 219,508 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $5.1M | 0.76% | 2,388,011 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $4.8M | 0.73% | 5,095,912 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc. | $4.4M | 0.66% | 2,409,862 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $3.3M | 0.50% | 89,715 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $2.4M | 0.37% | 330,000 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $524,500 | 0.08% | 50,000 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $80,280 | 0.01% | 11,518 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.